Labquality strengthens its Board of Directors with two experienced healthcare industry leaders

Labquality nominates Mathias Karlsson and Juergen Dobmeyer to its Board of Directors.

Labquality Corporation nominates two new members to its Board of Directors. MD PhD, Mathias Karlsson and Dr. Juergen Dobmeyer will join the Board of Directors with immediate effect. Mathias and Juergen are valuable additions to the board, having a lot of experience and strong knowledge of Labquality's target customer industries and segments. Their insight will leverage Labquality's international growth strategy design and implementation. They bring expertise and experience to Labquality's main business areas. Mathias contributes to the external quality assessment (EQA) business, whereas Juergen contributes to the clinical research (CRO) business.

"I am delighted to welcome Mathias and Juergen to the Labquality team. I trust they have the right EQA and CRO knowledge and experience to help lift our business to the next level," says CEO and Board Member Juha-Pekka Nuutinen from Labquality.

"I am very happy to welcome Mathias and Juergen to the Labquality Board of Directors. They both bring tremendous industry knowledge and longstanding experience that will help Labquality to open new business opportunities. On top of that, they will help us in the design and execution of our international growth strategy," concludes Jaana Grüter, Chairman of the Board of Labquality and Partner of Meriéux Equity Partners.

Mathias Karlsson, MD PhD, has extensive experience in medical technology, research and development, and entrepreneurship positions. His background includes research, clinical work, and several leadership roles, all marked by a solid commitment to quality and innovation in healthcare solutions. He is from the Karolinska Institute and has been working in the Swedish healthcare sector in different positions for over 30 years as a nurse, physician, and senior consultant in Clinical Chemistry. He also has a background in healthcare management as head of outpatient care in the county of Värmland. Mathias has a research background and is also the co-founder of two diagnostic start-ups. He has been Chief Medical Officer in the Nordics for IBM and recently served as CEO at Swedish EQA services provider Equalis AB. He currently holds the position of the Chief Medical Officer at the Swedish company Capitainer AB.

"It is an honour to join Labquality's board. The mission for Labquality aligns with my career-long aspiration to support patients and healthcare providers with new, high-quality solutions. I look forward to contributing to our efforts to promote healthcare quality globally," says Mathias Karlsson.

Dr. Juergen Dobmeyer is a highly accomplished clinical development expert, senior clinical research physician, research scientist, and development strategist. His distinguished career includes supporting pharmaceutical companies in various executive and board roles, showcasing his deep knowledge and leadership. He has served as Chief Medical Officer for several European start-up companies and as Clinical Operations Director for a Clinical Service Organization, where he successfully executed multiple global Ph1-NDA development programs. He has established lasting relationships with international Key Opinion Leaders and decision-makers in the pharmaceutical industry, Contract Research Organizations, and Functional Service Providers. Juergen has led teams of highly skilled professionals in executing complex clinical trials, resulting in the global marketing authorisation of new medicinal products.

"I am honoured to join Labquality as a non-executive board member and take on the responsibility of advancing our CRO business. Labquality's commitment to excellence in clinical investigation aligns perfectly with my professional values and vision for the future of clinical research. I look forward to collaborating with the talented team at Labquality to drive innovation and deliver high-quality services that meet the needs of our clients and partners. Together, we can make significant strides in advancing clinical research and improving patient outcomes," concludes Juergen Dobmeyer.

For queries, please contact:

Juha-Pekka Nuutinen
CEO | Labquality
+358 40 828 3210 | jp.nuutinen@labquality.com

Jaana Grüter
Partner | Mérieux Equity Partners
jaana.gruter@merieux-partners.com

Labquality
We create quality excellence in healthcare on every continent. That's our vision.

We are quality makers – a team of experienced experts in healthcare and health-tech quality. Our quality services for the healthcare, pharmaceutical and medical technology industries cover external quality assessments, regulatory consulting, clinical investigations and trials, audits and certifications, and training. Our expertise and knowledge benefit medical device and in vitro diagnostic manufacturers, pharmaceutical companies, healthcare units, and clinical laboratories.

Currently, we serve customers in over 60 countries. Our team comprises 150 skilled professionals, and our offices are in Finland, Poland, Sweden, and Germany.

For more information, please visit www.labquality.com.

Mérieux Equity Partners
Founded in 2009, Mérieux Equity Partners ("MxEP") is a leading European healthcare-specialized investment firm, with two dedicated platforms, Venture Capital and Buyout, supporting companies ranging from start-ups to established leaders. Benefiting from a longstanding expertise and a large network, MxEP invests in companies with ambitious growth projects and products or services transformative for Health. MxEP is AMF-accredited and currently manages c.€1.5bn of AuM. Labquality has been supported by Mérieux Equity Partners since November 2023.

For more information, please visit www.merieux-partners.com.